Zoetis Inc. (NYSE:ZTS) Shares Sold by Bamco Inc. NY

Bamco Inc. NY reduced its stake in Zoetis Inc. (NYSE:ZTS) by 9.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,700 shares of the company’s stock after selling 3,000 shares during the period. Bamco Inc. NY’s holdings in Zoetis were worth $4,856,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Blue Bell Private Wealth Management LLC boosted its position in Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after buying an additional 89 shares during the last quarter. Webster Bank N. A. boosted its position in Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the last quarter. Independence Bank of Kentucky boosted its position in Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after buying an additional 130 shares during the last quarter. Private Wealth Management Group LLC purchased a new position in Zoetis in the 4th quarter valued at about $33,000. Finally, Gladius Capital Management LP purchased a new position in Zoetis in the 4th quarter valued at about $40,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

ZTS traded up $3.01 on Monday, hitting $182.85. 502,231 shares of the company’s stock were exchanged, compared to its average volume of 2,810,711. The firm has a market cap of $83.43 billion, a PE ratio of 35.23, a P/E/G ratio of 2.79 and a beta of 0.86. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The stock has a fifty day moving average of $174.51 and a two-hundred day moving average of $176.00. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.04. The firm had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. Zoetis’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.31 earnings per share. On average, research analysts anticipate that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Piper Sandler reissued an “overweight” rating and issued a $195.00 price objective (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. BTIG Research started coverage on shares of Zoetis in a research report on Thursday. They set a “buy” rating and a $220.00 price target on the stock. Stifel Nicolaus reduced their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, April 30th. HSBC reduced their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Finally, Barclays reduced their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $212.67.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.